You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
藥明生物(02269.HK)擬在公開市場以不超3億美元總價格購回股份
格隆匯 09-26 07:58

格隆匯9月26日丨藥明生物(02269.HK)發佈公吿,根據購回授權,公司獲准於聯交所購回最多4.259億股股份,佔於股東周年大會當日已發行股份總數的10%。2022年9月23日,董事會已議決動用購回授權,以不時在公開市場上以不超過3億美元總價格購回股份。

董事會認為,股份的當前成交價未能反映其內在價值或集團的實際業務前景,併為公司提供進一步購回股份的良機。此外,公司的財務狀況維持穩健。董事會相信,建議股份購回及其後註銷所購回股份不僅可提升股份價值,從而改善股東回報,亦可減少集團各項股份獎勵計劃對公司股權潛在攤薄效應的影響。另外,建議股份購回反映公司對其自身價值的認可及對其強勁增長前景充滿信心。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account